Press releases
- Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
- Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
- Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
- Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
- Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 5.19 |
Low | 5.19 |
Bid | -- |
Offer | -- |
Previous close | 5.19 |
Average volume | -- |
---|---|
Shares outstanding | 1.29m |
Free float | 886.98k |
P/E (TTM) | -- |
Market cap | 2.86m USD |
EPS (TTM) | -29.21 USD |
Data delayed at least 15 minutes, as of Mar 10 2023 07:02 GMT.
More ▼